GlaxoSmithKline’s three long-term priorities are designed to create long-term value for patients, consumers, and shareholders.
Johnson & Johnson management has outlined a strategy to deliver above-market, compound annual growth for the company’s pharmaceutical business through 2023.
Merck’s extraordinary success with the immuno-oncologic Keytruda has pushed the company back to the pinnacle of the pharma industry.
Novartis is investing in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.
After a 2018 in which Pfizer reorganized the company’s businesses and built on a foundation for future growth, 2019 features a new executive chairman, the completion of a consumer health joint venture, the prospect of merging its legacy medicines company with Mylan and an $11.4 billion biotech acquisition.
Roche’s newer pharmaceutical products are generating stellar performances and have the company well-positioned for future growth.
Before his retirement in September 2019, CEO Olivier Brandicourt oversaw four years of Sanofi reshaping itself to overcome the effect of patent expirations for the company’s leading medicines.
The acquisition of Shire means that Takeda is as much an American company now as it is Japanese.
The Healthcare Businesswomen’s Association’s 2019 Annual Conference will be held in San Diego on November 11-12.
